ESLAW 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-13

• For the three months ended June 30, 2026 and 2025, general and administrative expenses were approximately $0.7 million and $0.9 million, respectively, representing a decrease of approximately $0.2 million, or 22.6%. The decrease was primarily attributable to lower legal and professional fees.

• For the three months ended June 30, 2026 and 2025, the Company recognized a loss from the change in fair value of derivative liabilities of approximately $0.2 million and $0, respectively. The loss was primarily attributable to the periodic remeasurement of the derivative liabilities associated with…

• Results of Operations for the Six Months Ended June 30, 2026 and 2025 (Unaudited)

• Research and development expenses consist primarily of costs related to conducting work related to the STARLIGHT-1 clinical trial, which is principally performed by Eureka under the SOW.

• For the six months ended June 30, 2026 and 2025, we incurred approximately $2.8 million and $6.1 million of research and development expenses, respectively. The decrease of approximately $3.3 million, or 53.9%, was primarily attributable to the timing of patient dosing and site activation milestones…

相对上期删除的文字 · 来源:10-Q · 2026-05-18

• Research and development expenses for both three months periods ended March 31, 2026 and 2025 each included costs associated with one patient dosed under SOW #001. Stock-based compensation allocated to research and development remained consistent at approximately $10,000 per quarter for both periods…

• For the three months ended March 31, 2026 and 2025, we incurred approximately $0.9 million and $0.7 million in general and administrative expenses, respectively. The increase of approximately $0.2 million, or 28.5%, was primarily attributable to higher legal and professional fees incurred to support…

• As of March 31, 2026, we had cash and cash equivalents of approximately $1.9 million and a working capital deficit of approximately $6.8 million. Since our inception, we have expended substantial funds on research and development and have experienced significant losses and negative cash flows from o…

• Net cash used in financing activities was approximately $29,000 for the three months ended March 31, 2025, consisting entirely of open market repurchases of our common stock under our stock repurchase program.

• We have entered into a series of short-term office sublease agreements with Eureka for 180 square feet of office space at a monthly fee of $2,000. The current sublease (Lease 5) commenced January 1, 2026 and expires June 30, 2026. As of March 31, 2026, total future minimum payments under Lease 5 are…